Xbrane Biopharma Ab · OMXSTO:XBRANE
Xbrane Biopharma Ab — Q2 2025 Earnings Presentation
19 slides from Xbrane Biopharma Ab's earnings presentation, Aug 26, 2025
Slide 1: Xbrane Biopharma Q2 2025 presentation
,RANE BIOPHARMA Q2 2025 present ation a - a mA |
Slide 2: Ximluci launched in 24 countries
“Ximluci® launched in 24 countries, volume growth +11% in Europe Q2 2025 vs Q1 2025” Wud Martin Amark, CEO August 26" , 2025 MBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2025 Interim Report 26/8/2025
Slide 3: Disclaimer
Disclaimer You must read the following before continuing, The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the "Company’) or any person on behalf of the Company and any ‘other material distributed or statements made in connection
Slide 4: Presenters
Presenters P Martin Amark Jane Benyamin CEO CFO MBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2025 Interim Report 26/8/2025
Slide 5: Ximluci launched across 24 countries
Ximluci® – Launched across 24 countries Ximluci® launched by STADA in 24 countries Co-Development & Commercialization Partnership with STADA Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally Global generics and biosimilar specialist with including
Slide 6: Ximluci currently at 8% volume market share in Europe
Ximluci® – Currently at 8% volume market share in Europe Profit split to Xbrane and growth in vials sold by STADA Commentary Volume growth Q2 2025 vs. Q1 2025 in Europe 11%, across all markets -8% due to quarterly variability in launch shipments to MENA countries Total profit generation by Xbran
Slide 7: Lucamzi upcoming US FDA BsUFA date October 21st
Lucamzi – upcoming US FDA BsUFA date October 21st Xbrane & STADA partner with Valorum US Commercialization Partnership Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, Biosimilar commercialization marketing and commercial efforts in the US
Slide 8: Lucamzi US poses a significant opportunity
Lucamzi – US poses a significant opportunity US retinal anti VEGF: USD 10 billion market Commentary ~8 million units Lucentis biosimilars covered under Medicare Part B with 20% 100% patient co-payment Reimbursement based on ASP* + 6-8% of originator ASP 80% Dynamic which favors new biosimilar
Slide 9: Xdivane CTA approval in first country triggering €2m milestone
Xdivane – CTA approval in first country triggering €2m milestone (in Q3) 2024 2025 2026 2027 2028 2029 2030 Commercialization Milestone payment to Milestone payment to Xbrane Xbrane LoE US LoE Europe Production of clinical material Pivotal clinical trial MAA / BLA Successful scale-up to Single p
Slide 10: Xdivane +1 billion SEK annual profit sharing potential
Xdivane – +1 billion SEK annual profit sharing potential for Xbrane US biosimilar volume market share vs. reference product Commentary Oncology biosimilars have been well received with average penetration of 75% at year 3 post launch in US Sold via hospital channel in US under Medicare Part B re
Slide 11: Jan-June Interim Report 2025 Financials
GAR IMM7F Jan-June Interim Report 2025 Financials Ha Sd 3 a HT), | i Z MUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS
Slide 12: Net Revenues (Quarter by Quarter)
Net Revenues (Quarter by Quarter) Net revenue Commentary on 5) SEK m Q2'24 Q3'24 0424 125225 Gross margin 100,0 140% % > Revenue Q2 2025 ~ 39.9 MSEK, Gross Margin 100% 126% MSEK Revenue Q2 2024 ~ 52.0 MSEK 120% 80,0 100% ; gq > Milestone attributable to the license agreement with Intas Pharmaceutica
Slide 13: Company Expenses (G&A and R&D) by Quarter
Company Expenses (G&A and R&D inc. capitilized R&D) by Quarter SEK m Q2 '24 Q3 124 Q4'24 Q1'25 Q2'25 0,0 98 10. “10 -10,0 18,3 -20,0 > Administration expenses amounted to 18.3 MSEK for Q2 en whereof 9 MSEK corresponding to non-recurring items ~ connected to the transaction with Alvotech -40,0 -50,0
Slide 14: Cash flow Q2-25
Cash flow Q2-25 275 -5 -153 -90 25 -47 6
Slide 15: Cash and Cash Equivalents / Operating Cash Flow
Cash and Cash Equivalents Operating Cash Flow
Slide 16: Q2 2025, Key Take-Aways
Q2 2025, Key Take-Aways Ximluci® launched in 24 countries, volume growth in Europe +11% Q2 2025 vs Q1 2025 Xdivane progressing according to plan, triggering €2m milestone payment (in Q3) Strategic sale to Alvotech has resulted in significant reduction of debt and reduced cost structure Directed shar
Slide 17: Key Priorities for 2025 and 2026
Key Priorities for 2025 and 2026 Upcoming Ximluci US FDA BsUFA date October 21st and ongoing preparations for US launch Support STADA in continued penetration of Europe/MENA market for retinal anti-VEGFs including resumed commercial manufacturing during H2 2025 Initiatives to reduce Ximluci producti
Slide 18: Business Concept
BUSINESS CONCEPT Xbrane develops biosimilars of difficult-to- manufacture and often very expensive original drugs VISION To become a world-leading scientifically-based biosimilar developer of cost-effective drugs for which there is a significant medical need OBJECTIVE To contribute to everybody havi
Slide 19: Jan - June 25 Interim Report
MUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILA January - June 2025 Interim Report